Switch theme
Sign up to access all valuation multiples
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
1997
10.0K+
LTM Revenue $1.6B
LTM EBITDA $351M
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
China Res Double-Crane has a last 12-month revenue (LTM) of $1.6B and a last 12-month EBITDA of $351M.
In the most recent fiscal year, China Res Double-Crane achieved revenue of $1.6B and an EBITDA of $366M.
China Res Double-Crane expects next 12-month revenue of XXX and NTM EBITDA of XXX
See China Res Double-Crane valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Profit | $908M | XXX | $891M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $351M | XXX | $366M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $265M | XXX | $235M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $232M | XXX | $226M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, China Res Double-Crane's stock price is CNY 20 (or $3).
China Res Double-Crane has current market cap of CNY 20.3B (or $2.8B), and EV of CNY 18.3B (or $2.5B).
See China Res Double-Crane trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.8B | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, China Res Double-Crane has market cap of $2.8B and EV of $2.5B.
China Res Double-Crane's trades at 1.6x EV/Revenue multiple, and 7.0x EV/EBITDA.
Equity research analysts estimate China Res Double-Crane's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
China Res Double-Crane has a P/E ratio of 12.1x.
See valuation multiples for China Res Double-Crane and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 7.3x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | 10.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 12.1x | XXX | 12.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 15.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChina Res Double-Crane's last 12 month revenue growth is 4%
China Res Double-Crane's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
China Res Double-Crane's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
China Res Double-Crane's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for China Res Double-Crane and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China Res Double-Crane acquired XXX companies to date.
Last acquisition by China Res Double-Crane was XXXXXXXX, XXXXX XXXXX XXXXXX . China Res Double-Crane acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was China Res Double-Crane founded? | China Res Double-Crane was founded in 1997. |
| Where is China Res Double-Crane headquartered? | China Res Double-Crane is headquartered in China. |
| How many employees does China Res Double-Crane have? | As of today, China Res Double-Crane has 10.0K+ employees. |
| Is China Res Double-Crane publicy listed? | Yes, China Res Double-Crane is a public company listed on SHG. |
| What is the stock symbol of China Res Double-Crane? | China Res Double-Crane trades under 600062 ticker. |
| When did China Res Double-Crane go public? | China Res Double-Crane went public in 1997. |
| Who are competitors of China Res Double-Crane? | Similar companies to China Res Double-Crane include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of China Res Double-Crane? | China Res Double-Crane's current market cap is $2.8B |
| What is the current revenue of China Res Double-Crane? | China Res Double-Crane's last 12 months revenue is $1.6B. |
| What is the current revenue growth of China Res Double-Crane? | China Res Double-Crane revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of China Res Double-Crane? | Current revenue multiple of China Res Double-Crane is 1.6x. |
| Is China Res Double-Crane profitable? | Yes, China Res Double-Crane is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of China Res Double-Crane? | China Res Double-Crane's last 12 months EBITDA is $351M. |
| What is China Res Double-Crane's EBITDA margin? | China Res Double-Crane's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of China Res Double-Crane? | Current EBITDA multiple of China Res Double-Crane is 7.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
